Product
Placebo for Risankizumab
1 clinical trial
1 indication
Indication
Crohn's diseaseClinical trial
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's DiseaseStatus: Active (not recruiting), Estimated PCD: 2026-06-09